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To describe trajectories of health‐related quality of life (QoL), life satisfaction,

and psychological adjustment for men with prostate cancer over the medium to long term and
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identify predictors of poorer outcomes using growth mixture models.
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One‐thousand sixty‐four (82.4% response) men diagnosed with prostate cancer

were recruited close to diagnosis and assessed over a 72‐month (6‐year) period with self‐report
assessment of health‐related QoL, life satisfaction, cancer‐related distress, and prostate specific
antigen anxiety. Urinary, bowel, and sexual function were also assessed using validated
questionnaires.

Results

Poorer physical QOL was predicted by older age, lower education, lower income,

comorbidities, and receiving hormone therapy. Lower life satisfaction was related to younger
age, lower income, not being partnered, and comorbidities. Poorer psychological trajectories were
predicted by younger age, lower income, comorbidities, and receiving radical prostatectomy or
brachytherapy. Better urinary, bowel, and sexual function were related to better global outcomes
over time. Anxiety about prostate specific antigen testing was rare.

Conclusions

Distinct trajectories exist for medium‐ to long‐term QoL, life satisfaction, and

psychological adjustment after prostate cancer; with age and socioeconomic deprivation playing
a differential role in men’s survivorship profile and the impact of functional status on outcomes
increasing over time. These results reinforce the need for an appraisal of men’s life course in
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addition to treatment side effects when planning survivorship care after cancer.
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countries in 2012 alone (75% of global incidence).1 Five‐year relative

I N T RO D U CT I O N

survival for this cancer now approaches 100% in some countries for
Prostate cancer is the most common cancer among men in developed

those diagnosed at a localised stage,2 although there were still an esti-

countries, with an estimated 740 000 men diagnosed in these

mated 140 000 deaths due to prostate cancer in developed countries

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
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in 2012.1 There is often a long time frame between prostate cancer

Thus, our aim in the current study was to examine the trajectories

diagnosis and death, with men continuing to have excess mortality

of health‐related QoL, life satisfaction, and psychological adjustment

up to 15 years after diagnosis,3 and dying from their prostate cancer

in men previously diagnosed with prostate cancer who were

more than 20 years after diagnosis.4 This means prostate cancer

followed over a 6‐year period. We examined socio‐demographic

survivorship for many men is a long‐lived experience, with quality

predispositional and clinical factors as well as time varying functional

of life (QoL) and psychological well‐being crucial considerations in

outcomes as predictors to identify characteristics of men “at risk” for

care after diagnosis. To date, there is limited data on long‐term

poorer outcomes across treatment types.

survivorship (>5 years post diagnosis) in general, and this is more
so with regards to the survivorship experience of men with prostate

2

cancer.5

METHOD

|

To date, the domain‐specific QoL effects of treatment for prostate
cancer have been well described. These include urinary, bowel, and
sexual dysfunction, as well as effects specific to hormone ablation
therapy with these effects differing by treatment approach. For example, 5 years after diagnosis men treated with radical prostatectomy
(RP) experience worse urinary incontinence, but similar sexual outcomes, compared to men treated with radiation therapy.6 By contrast,
men treated with radiation therapy experience more long‐term
adverse effects on bowel function with androgen deprivation having
7

the greatest adverse effect on physical QoL. Studies relating to overall
health‐related QoL suggest that men’s mental and physical wellbeing
are stable in the medium to long term. However, the predominant
focus on domain‐specific effects leaves gaps in our understanding of
the impact of prostate cancer on men’s global QoL and may obscure
patient subgroups who do not fare well over time.
Even less is known about the course of long‐term psychological
adjustment after prostate cancer, with distress estimates close to
8

diagnosis varying from 10% to 23%. Depression and anxiety seem
to be highest at treatment commencement for men with localised
and locally advanced prostate cancer, reducing to levels below or
similar to that of the general population after 12 months.9 To date,
there is scant research examining long‐term (>5 years) psychological
adjustment after prostate cancer, with limitations including the use of
non‐validated asesssments.10 For those studies that did apply well
validated measures, 1 group reported that 10% of men with localised

2.1

Participants

|

These data are from a longitudinal study of men newly diagnosed with
prostate cancer in Queensland.18–20 Ethical approval was obtained
from the Queensland University of Technology Human Research
Ethics Committee and ethics committees of 10 public hospitals in
Queensland. Men newly diagnosed with prostate cancer from the
geographic catchment areas of South East and North Queensland,
Australia, were recruited between March 2005 and September 2007.
Eligibility criteria included ability to read, write, and speak English; no
history of dementia, head injury or psychiatric illness; and regular
access to a telephone. Urologists referred men to the study if they
were newly diagnosed with prostate cancer irrespective of stage of
disease. Of the 1291 men referred to the study, 1064 (82.4%) were
eligible and consented to participate. Participants completed assessments at baseline, and 2, 6, 12, 24, 36, 48, 60, and 72 months after
the start of treatment. Baseline assessments were completed for
1034 (97%) men. In all, 575 (54% from eligible and consented) men
completed assessments at all 9 time points, with 357 men withdrawing
from the study between baseline and 72 month assessment.
Self‐report measures were administered by mail at each time point.
Of the total sample, 41 men had died at 6 years. Other reasons for
attrition included being too unwell, not contactable, and not wanting
to think about prostate cancer anymore.

prostate cancer experience clinically significant depression up to
8 years after treatment.11 By contrast, Korfage et al (2006) reported

2.2

Predictor variables

|

that one in 4 men (28%) with prostate cancer were highly anxious
before treatment; although by 6 months, this reduced with most men
12

experiencing low distress at 5 years.

These studies however were

not able to assess for heterogeneity in trajectories of adjustment and
so were limited in their ability to longitudinally identify risk factors

Socio‐demographic variables including age, marital status, education
and income, and clinical variables such as chronic health conditions,
treatment type, time since diagnosis, prostate specific antigen (PSA),
Gleason score, and stage were collected at baseline.

for distress and patterns of change.
In this regard, growth mixture models (GMMs) have been widely
used to assess for heterogeneity of trajectories of scores within a

2.3

Outcome variables

|

population.13 Growth mixture models allow different statistical distri-

2.3.1

butions for analysing various types of score variables, the identification

The Short Form 36 (SF‐36) assessed health‐related QoL.21 Two global

of differential features among trajectory classes, and the inclusion of

measures of psychological and physical functioning are derived (mental

time‐varying covariates for modelling the association between the

health domain and physical health domain) whereby higher scores

score variable and predictors at each measurement time point.14,15

indicate better health‐related QoL.

|

Quality of life

By applying this approach in our previous research with colorectal

Disease‐specific QoL was measured using the expanded prostate

cancer patients, we identified unique patterns of risk that were associ-

cancer index composite (EPIC)22 assessing urinary, bowel, and sexual

ated with distinct psychological adjustment and QoL trajectories.16,17

function domains. All EPIC scores were standardised to a 0 to 100

To date, to our knowledge, this approach has not been applied to

scale. Higher scores indicate better QoL. Internal reliability among

examine men’s adjustment to prostate cancer.

the 3 EPIC function summary scores ranged from α = 0.76 to 0.95
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(urinary, α = 0.83 to 0.86; bowel, α = 0.83 to 0.90; and sexual, α = 0.90

were checked for evaluating the impact of missing data in outcome

to 0.95).

variables on model convergence. Missing values in the EPIC
time‐varying covariates were computed using the multiple imputation

2.3.2

method with restriction to a 0 to 100 scale.31 In the first stage, the

Satisfaction with life

|

The satisfaction with life scale (SWL)23 assessed participants’ subjec-

missing EPIC subscales were imputed based on the characteristics of

tive cognitive well‐being (α = 0.88 to 0.91). Higher scores indicate a

the observed EPIC subscales, and this procedure was repeated 10

higher satisfaction with life.

times to generate 10 imputed data sets. In the second stage, the
GMMs were fitted separately to each of the imputed data sets and

2.3.3

the results were pooled into a final set of estimates.31,32 Individuals

Cancer‐related distress

|

The revised impact of event scale (RIES)24 assessed cancer‐specific

(N = 120) with more than 6 missing values in the EPIC time‐varying

distress at baseline through to 60 months. The RIES contains 3

covariates were excluded for the analyses. This reduced the sample

subscales: intrusion (α = 0.87 to 0.91), avoidance (α = 0.84 to 0.87),

size from 1064 to 944 in the GMMs. Patients with missing values in

and hyperarousal (α = 0.83 to 0.87). Higher scores indicate higher

other covariates were also excluded in the analyses.
Due to the fact that the proportion of 0 MAX‐PC scores was very

cancer‐specific distress. The RIES was not administered after 5 years

high at each time point (79‐93%), it is not possible to obtain a robust

to reduce participant burden.
The PSA anxiety subscale of the memorial anxiety for prostate

estimation of GMMs (with 0‐inflated models) for the longitudinal anal-

cancer (MAX‐PC) scale25,26 assessed distress related to PSA testing

ysis of MAX‐PC scores. Thus, descriptive statistical analyses were per-

(α = 0.60 to 0.77). Higher scores indicate higher distress.

formed to illustrate the distribution of MAX‐PC scores over time.

2.4

|

Statistical analyses

3
15,27

Growth mixture models in Mplus Version 6.12

RESULTS

|

were used to iden-

tify trajectory classes and predictors of membership in these classes,

Demographic and clinical characteristics of the study samples are pro-

separately for the QoL SF36 (physical health domain and mental health

vided in Table 1. The mean age of men at recruitment was 63.7 years;

domain), the SWL score, and the cancer‐related distress RIES score.

82.7% were married with the remainder divorced, widowed, or never

Nonlinear GMMs (consisting of intercept, slope, and quadratic growth

married; 53.3% had completed trade or university education, and the

parameters) were adopted to model individual growth trajectories

remainder had high school or less schooling; 43% had an annual

from unobserved (latent) subpopulations, where individual variation

income of $40 000AUS or less, 24.7% between $40 000 to

in growth parameters (intercept and slope) was captured by random

$80 000AUS and 21.9% > $80 000AUS. The average self‐reported

The association

PSA level at baseline was 11.0; the average Queensland cancer registry

between the EPIC (urinary, bowel, and sexual) functions and outcome

Gleason score was 7; the average time since diagnosis at recruitment

variables at each of the time points was modelled by including the 3

was 142 days; 92.1% of men had localized stage disease; 6.3% had

function subscales in the GMMs as time‐varying covariates at each

locally advanced stage; only 1.6% had advanced stage; 46.3% had

14,28

effects with different variance components.

received a RP; 38.3% had external beam radiation therapy; and

13

time point.

The RIES scores were heavily right‐skewed, with around 10‐45%

16.7% had received brachytherapy (BT).

of 0 scores at each of the time points. Thus, the GMMs with Poisson
and negative binomial distributions (including 0‐inflated models) were
considered for the longitudinal analysis of the RIES scores over time.15

3.1

|

Quality of life: physical health

Model selection was determined using the Bayesian information

Three distinct classes of trajectory patterns were identified for the

criterion.29

QoL SF36 (physical health domain) using GMM (Figure 1A). The

With GMMs, the initialization of growth parameters was obtained

constant high QoL class (Class 3) indicates a group of patients

by implementing a latent class growth analysis (assuming no within‐

(50.3%) who had constantly high physical health throughout the

class variance) fitted to the data. The GMM analyses were

6‐year follow‐up period. Class 2 represents a group of patients

implemented with 100 random sets of starting values and 10 final opti-

(30.2%) whose physical health started at a medium level and then

mizations. The number of trajectory classes K was determined using

at 3 years post‐diagnosis began to decrease. Class 1 (19.5% of

30

Covariates were

patients) indicates a physical health trajectory pattern, which

then entered into the K‐class (unconditional) GMM via multinomial

decreased steadily from a medium level and then increased at

logistic regression that compares the reference class (high‐SF36

4 years post‐diagnosis.

the Lo‐Mendell‐Rubin likelihood ratio test statistic.

domain or SWL scores, or low RIES score) with the other trajectory
classes (lower SF36 domain or SWL scores, or higher RIES scores).

Three predictors that significantly (P < .05) differentiated the
physical health trajectory classes with the constant high QoL (Class 3)

Missing data in outcome variables (SF36 domain, SWL, and RIES

as the comparison class were identified within the GMMs (Table 2A).

scores) were handled in Mplus using a robust full information maxi-

In comparison with the constant high QoL class, Class 2 (medium

mum likelihood estimation procedure with the missing at random

decrease) was characterized by patients with high levels of comorbid-

assumption that the missing scores are unrelated to the outcome

ity (adjusted odds ratio [OR] = 2.26, 95% confidence interval

variables.30 Estimates of covariance coverage for each pair of variables

[CI] = 1.09‐4.68 for 1‐2 conditions; adjusted OR = 6.81, 95%

CHAMBERS
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TABLE 1 Demographic and clinical characteristics of study samples
(N = 1064)

Characteristics
Age at recruitment (years)

Count (%) or Mean (SD)
63.7 (7.8)

(adjusted OR = 12.76, 95% CI = 2.48‐65.7 for income <$40 000;
adjusted OR = 9.15, 95% CI = 1.70‐49.3 for income between
$40 000 and $80 000), patients with ≥3 comorbid conditions
(adjusted OR = 9.51, 95% CI = 3.84‐23.5), and patients who did
not receive RP (adjusted OR = 0.13, 95% CI = 0.05‐0.34) or BT

Marital status
Married/defacto

880 (82.7%)

(adjusted OR = 0.25, 95% CI = 0.10‐0.59). Moreover, Class 1 was

Divorced/separated

110 (10.4%)

characterized by patients who received hormone therapy (adjusted

Widowed

27 (2.5%)

Never married

47 (4.4%)

3.2

Education level
Primary school/not complete
primary

145 (13.6%)

Junior high school

247 (23.3%)

Senior high school

104 (9.8%)

Trade/diploma

366 (34.5%)

University

200 (18.8%)

Missing

2

<$40 000

454 (43.0%)

$40 000‐$80 000

261 (24.7%)

>$80 000

231 (21.9%)

Not answer/don’t know

110 (10.4%)

PSA level at diagnosis
Missing
QCR Gleason score
Missing
Time since diagnosis at recruitment
(days)

8
11.0 (27.5)
151
7.0 (0.9)
70
142 (254)

QoL SF36 (mental health domain) using GMM (Figure 1B). The
Constant High QoL class (Class 3) indicates a group of patients
(62.3%) who had constantly high mental health throughout the 6 year
follow‐up period. Class 2 represents a group of patients (20.4%) whose
mental health increased initially and then at 3‐years post‐diagnosis
health trajectory pattern which decreased initially and then increased
at 3‐years post‐diagnosis.
Two predictors that significantly (P < .05) differentiated the mental
health trajectory classes with the constant high QoL as the comparison
class were identified within the GMMs (Table 2B). Compared to the
constant high QoL class, Class 2 was characterized by patients with
high levels of comorbidity (adjusted OR = 2.69, 95% CI = 1.18‐6.12
for 1‐2 conditions; adjusted OR = 3.84, 95% CI = 1.51‐9.75 for ≥3
conditions). Compared to the constant high QoL class, Class 1 was
differentiated by patients with household income <$40 000 (adjusted
conditions (adjusted OR = 3.26, 95% CI = 1.50‐7.07).

67 (6.3%)

Advanced

17 (1.6%)
2

3.3

|

Satisfaction with life

Three distinct classes of trajectory patterns were identified for SWL
using GMM (Figure 1C). The constant high SWL class (Class 3)

Comorbidity
0 conditions

175 (16.6%)

1‐2 conditions

556 (52.8%)

≥3 conditions

323 (30.6%)

Missing

Three distinct classes of trajectory patterns were identified for the

978 (92.1%)

Locally advanced

Missing

Quality of life: mental health

OR = 2.55, 95% CI = 1.30‐5.00) and patients with ≥3 comorbid

Stage
Localized

|

began to decrease. Class 1 (17.3% of patients) indicates a mental

Household income

Missing

OR = 2.95, 95% CI = 1.29‐6.71).

10

indicates a group of patients (63.0%) who had constantly high SWL
throughout the 6‐year follow‐up period. Class 2 represents a group
of patients (31.8%) whose SWL was maintained at a low level
constantly. Class 1 (5.2% of patients) indicates a SWL trajectory
pattern, which decreased from a medium level and then increased at

Therapy performed
Radical prostatectomy

493 (46.3%)

External beam radiation

407 (38.3%)

Brachytherapy

178 (16.7%)

Hormone therapy

385 (36.2%)

Watchful waiting

59 (5.5%)

3‐years post‐diagnosis.
Four predictors that significantly (P < .05) differentiated the SWL
trajectory classes with the constant high satisfaction as the comparison
class were identified within the GMMs (Table 2C). In comparison with
the constant high satisfaction class, Class 2 (low constant) was characterized by patients who were never married/widowed/divorced/sepa-

Abbreviations: PSA, prostate specific antigen; QCR, Queensland cancer
registry.

rated (adjusted OR = 2.68, 95% CI = 1.61‐4.48), younger age (adjusted
OR = 1.10 per 1‐year decrease in age, 95% CI = 1.06‐1.13), and
patients with household income <$40 000 (adjusted OR = 2.24, 95%

CI = 2.80‐16.5 for ≥3 conditions) and patients who did not receive

CI = 1.24‐4.05) and ≥3 comorbid conditions (adjusted OR = 3.17,
95% CI = 1.73‐5.80).

RP (adjusted OR = 0.24, 95% CI = 0.10‐0.57) or BT (adjusted
OR = 0.24, 95% CI = 0.11‐0.55). Class 2 was also characterized by
patients who received hormone therapy (adjusted OR = 2.39, 95%

3.4

CI = 1.08‐5.31). Compared to the constant high QoL class, Class 1

Three distinct classes of trajectory patterns were identified for can-

was differentiated by patients with lower household income

cer‐related distress (RIES) using GMM with a negative binomial

|

Cancer‐related distress

1580
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FIGURE 1

Trajectory patterns identified using growth mixture models: A, quality of life SF36, physical health domain (N = 928); B, quality of life
SF36, mental health domain (N = 928); C, satisfaction with life (SWL) score (N = 928); D, cancer‐related distress revised impact of event scale (RIES)
score (N = 934)

model (Figure 1D). Cancer‐related distress dropped significantly in

the comparison class were identified within the GMMs (Table 2D). In

the first half year of the follow‐up period for all 3 classes. The low

comparison with the low RIES class, Class 2 (medium RIES) was

cancer‐related distress class (Class 3) indicates a group of patients

characterized by patients who were younger in age (adjusted OR = 1.03

(39.0%) who had low cancer‐related distress throughout the 5 year

per 1‐year decrease in age, 95% CI = 1.00‐1.06) and who received RP

follow‐up period. Class 2 represents a group of patients (49.2%)

(adjusted OR = 2.28, 95% CI = 1.11‐4.69) or BT (adjusted OR = 2.30,

whose cancer‐related distress maintained at a medium level. Class 1

95% CI = 1.35‐3.91). Compared to the low RIES class, Class 1 (high

(11.8% of patients) indicates a cancer‐related distress trajectory

RIES) was differentiated by patients who were younger in age (adjusted

pattern, which was maintained at a higher level.

OR = 1.08 per 1‐year decrease in age, 95% CI = 1.04‐1.13) and had high

Three predictors that significantly (P < .05) differentiated the

levels of comorbidity (adjusted OR = 3.56, 95% CI = 1.31‐9.65 for 1‐2

cancer‐related distress trajectory classes with the low RIES score as

conditions; adjusted OR = 5.57, 95% CI = 1.92‐16.1 for ≥3 conditions).

CHAMBERS
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Predictors of trajectory class membership for various outcome measures

Predictor

Adjusted OR (95% CI) relative to constant high class (Class 3)
Class 2

Class 1

<$40 000

1.83 (0.96, 3.47)

12.76* (2.48, 65.7)

$40 000‐$80 000

1.33 (0.59, 3.00)

9.15* (1.70, 49.3)

P valuea

(A) Quality of life SF36 (physical health domain, N = 928)
Household income

>$80 000
Not answer/do not know

<.001

Reference
1.71 (0.70, 4.20)

Reference
5.30 (0.83, 33.8)

Comorbidity
0 condition

<.001
Reference

Reference

1‐2 conditions

2.26* (1.09, 4.68)

1.99 (0.88, 4.52)

≥3 conditions

6.81* (2.80, 16.5)

9.51* (3.84, 23.5)

Therapy performed vs nil
Radical prostatectomy
External beam radiation

<.001
0.24* (0.10, 0.57)

0.13* (0.05, 0.34)

1.02 (0.51, 2.04)

0.43 (0.18, 1.00)

Brachytherapy

0.24* (0.11, 0.55)

0.25* (0.10, 0.59)

Hormone therapy

2.39* (1.08, 5.31)

2.95* (1.29, 6.71)

Watchful waiting

1.12 (0.41, 3.08)

0.49 (0.16, 1.56)

<$40 000

1.44 (0.74, 2.82)

2.55* (1.30, 5.00)

$40 000‐$80 000

1.40 (0.72, 2.71)

1.33 (0.62, 2.85)

(B) Quality of life SF36 (mental health domain, N = 928)
Household income

>$80 000
Not answer/don’t know

.008

Reference
0.84 (0.32, 2.24)

Reference
1.33 (0.49, 3.61)

Comorbidity
0 conditions

<.001
Reference

Reference

1‐2 conditions

2.69* (1.18, 6.12)

1.71 (0.82, 3.58)

≥3 conditions

3.84* (1.51, 9.75)

3.26* (1.50, 7.07)

1.10* (1.06, 1.13)

1.00 (0.93, 1.08)

(C) Satisfaction with life (SWL, N = 928)
Age (younger)
Marital status
Married/defacto
Never married/widowed/divorced/separated

<.001
Reference
2.68* (1.61, 4.48)

Reference
1.07 (0.34, 3.33)

Household income
<$40 000
$40 000‐$80 000
>$80 000
Not answer/don’t know

.022
2.24* (1.24, 4.05)

1.85 (0.60, 5.74)

1.40 (0.81, 2.44)

0.80 (0.24, 2.75)

Reference
0.91 (0.41, 2.00)

Reference
0.57 (0.10, 3.31)

Comorbidity
0 conditions

<.001

<.001
Reference

Reference

1‐2 conditions

1.74 (0.99, 3.04)

0.83 (0.35, 1.98)

≥3 conditions

3.17* (1.73, 5.80)

0.29 (0.07, 1.28)

1.03* (1.00, 1.06)

1.08* (1.04, 1.13)

(D) Cancer‐related distress (RIES, N = 934)
Age (younger)
Comorbidity
0 conditions

<.001
Reference

Reference

1‐2 conditions

1.02 (0.65, 1.58)

3.56* (1.31, 9.65)

≥3 conditions

1.09 (0.64, 1.85)

5.57* (1.92, 16.1)

Therapy performed vs nil

<.001

.003

(Continues)
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(Continued)

Predictor

Adjusted OR (95% CI) relative to constant high class (Class 3)
Class 2

P valuea

Class 1

Radical prostatectomy

2.28* (1.11, 4.69)

0.56 (0.17, 1.81)

External beam radiation

2.30* (1.35, 3.91)

0.54 (0.21, 1.36)

Brachytherapy

0.98 (0.56, 1.71)

0.39 (0.13, 1.17)

Hormone therapy

1.15 (0.64, 2.09)

1.38 (0.65, 2.94)

Watchful waiting

2.14 (0.90, 5.12)

0.77 (0.15, 4.01)

Abbreviations: CI, confidence interval; OR, odds ratio; RIES, revised impact of event scale; SWL, satisfaction with life scale.
*significant at 0.05 level on the adjusted log odds of being in the class versus Class 3
a

likelihood ratio test (full model versus model without the predictor under consideration)

3.5

|

PSA anxiety

The proportion of 0 MAX‐PC scores or PSA anxiety was high at each
time point. In brief, 79.1% of patients had 0 PSA anxiety at baseline,
and this increased gradually during the follow‐up period. At 6‐years
post‐diagnosis, the proportion of men with no PSA anxiety was
92.6%. For those patients with PSA Anxiety (nonzero MAX‐PC scores),
the mean score was 2.33 at baseline, which declined slightly during the
follow‐up period (however, an increase of mean scores was observed
at 1‐ and 4‐years post‐diagnosis). At 6‐years post‐diagnosis, the mean
PSA Anxiety score was 2.08. The improvement in PSA anxiety was also
reflected by the lowered maximum PSA anxiety among the patients.
From 5‐years post‐diagnosis, there were no patients with PSA anxiety
scores greater than 6.

psychological demands that come with living with cancer, may be
heightened. Similar to previous research,34 older men were more at
risk for poorer physical QoL that may link to the comorbidities associated with age that increase the physical challenges of treatment.
Indeed, comorbidities themselves were associated with poorer physical and mental well‐being highlighting the burden of chronic illness
more broadly in this patient population. For QoL, life satisfaction and
psychological distress, the man’s income and level of education were
variously associated with poorer outcomes, reflecting the important
role of economic advantage as a coping resource. This finding is also
consistent with previous research showing men with low health literacy are more vulnerable to poorer mental health after prostate cancer.35 Finally, men who were un‐partnered were also at risk of
greater psychological distress, with this a likely indicator of low social
support. From this, we propose that an appraisal of a man’s life course

3.6

|

Time‐varying effects of the EPIC subscales

The effects of the EPIC urinary, bowel, and sexual function on the 4
outcome variables at each of the time points are displayed in
Figure 2. Generally, higher EPIC function significantly increased the
patient’s QoL, SWL, and reduced cancer‐related distress. The effects
of bowel function on physical and mental health and cancer‐related
distress were larger compared to urinary and sexual function. For cancer‐related distress, the effects of the EPIC functions were larger
approximately 24‐36 months post‐diagnosis, relative to the effects just
after diagnosis (Figure 2D). This indicates that the effects of function
on cancer‐related distress increases over time.

and situation is an essential first step for an effective and well‐targeted
survivorship plan.33
We observed, over time, an increasing negative effect of poor
sexual, urinary, and bowel function on cancer‐specific distress, peaking
at 2‐ to 3‐years post diagnosis. Impacts of these areas of function for
many men are long term, and these data suggest that rather than
men learning to live with it, functional deficits over time may amplify
avoidant and intrusive thinking about cancer, as well as hyperarousal
or physical symptoms of distress. This is particularly striking given
the relative absence in this large cohort of PSA anxiety, although this
finding may reflect that rather than being pervasive, PSA anxiety is
centred more around specific time points (eg, clinical checkups).
Sexual, urinary, and bowel function therefore may be of more concern

4

|

DISCUSSION

to men over the course of their survivorship experience than frequent
PSA testing, and this may have implications for decision making about

The present results suggest particular characteristics for men with a

surveillance approaches to early prostate cancer. Finally, hormone

diagnosis of prostate cancer that predict, over the medium and long

therapy was associated with poorer physical well‐being, underlining

term, poorer QoL and psychological outcomes. First, if men are youn-

the burden this treatment type carries for men with prostate cancer.

ger at the time of diagnosis, they can be expected to be at greater risk

Receiving RP or BT was predictive of men experiencing some cancer‐

for experiencing higher cancer‐related distress and poorer life satisfac-

related distress; however, the reasons for this are unclear.

tion. There are a number of reasons why younger men may be more

Importantly, it is clear that the course of adjustment for many men

likely to experience these outcomes that reflect the greater disruption

will not be linear. Ongoing assessment of function as well as QoL and

of life goals and circumstances when cancer occurs at a younger age.33

psychological distress is needed into the medium and long term, with

Younger men may still be building or consolidating careers, be more

linked accessible support systems. In many settings, this will require

sexually active, and have greater financial responsibilities than older

the integration of primary and community care services as men leave

men. From this, the burden of cancer, and the uncertainty and

the acute treatment system. To date, peer support has been a leading
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FIGURE 2

Effects from the expanded prostate cancer index composite (EPIC) urinary, bowel, and sexual functions on A, SF36 physical health, B,
SF36 mental health, C, satisfaction with life (SWL), and D, revised impact of event scale (RIES): a positive value of effects means that a higher EPIC
function increases the score of the outcome variable, while a negative value indicates that a higher EPIC function decreases the score of the
outcome variable

model of care in the community36,37 and it seems likely that as preva-

illness on outcomes. As well, we did not have matched controls as a

lence and the health costs of prostate cancer increase, so too will the

comparison group. As a further comment, masculinity is increasingly

importance of peer support in survivorship care. Future research to

acknowledged as influential in men’s response to prostate cancer.38

develop and evaluate integrated long‐term survivorship care systems

There is a need for future research to include masculinity as a potential

is needed.

mediator or moderator of adjustment outcomes that will be aided by

Limitations of the current study include the use of a nonrepresen-

the recent development of a context specific measure for this

tative sample and the extent of study attrition over time. Specifically,

purpose.38 Study strengths include the high response rate, large sam-

the cohort was more likely to be have been diagnosed with intermedi-

ple, application of well validated and reliable measures, and long‐term

ate than advanced prostate cancer compared to all men diagnosed

(>5 years) follow‐up. In addition, the application of GMMs presents a

20

with prostate cancer in Queensland during the same period.

This

new picture of posttreatment adjustment not previously presented,

means that generalisability to the population should be approached

providing a more accurate picture of differences in individual change

cautiously and that we were unable to explore the effect of stage of

over time than the conventional growth model and the latent class

1584

growth analysis method while allowing also for nonlinear change to be
described.
In conclusion, prostate cancer survivorship is a neglected area of
research.39 Medium‐ to long‐term survivorship care plans for men with
prostate cancer will need to consider the influence of age, partner
status, and social disadvantage and comorbidities, as well as urinary,
sexual, and bowel function, on men’s QoL and psychological outcomes.
A holistic approach that considers life course as well as medical
treatment regimens is needed. For many men, the path of recovery
and survivorship will not be linear, with the implication that regular
assessment of progress towards optimal well‐being is needed over
the medium to long term, with care plans adjusted to meet emerging
issues.
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